Covered recipient · General Payments record
NILANJAN GHOSH
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$131,531.04
155 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $77,146.00 | 29 |
| Travel and Lodging | $30,577.12 | 59 |
| Consulting Fee | $16,475.00 | 9 |
| Food and Beverage | $3,737.92 | 56 |
| Honoraria | $3,500.00 | 1 |
| Education | $95.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $27,888.60 | 24 |
| Celgene Corporation | $17,601.36 | 22 |
| Kite Pharma, Inc. | $17,008.06 | 20 |
| Genentech, Inc. | $12,195.71 | 4 |
| Seattle Genetics, Inc. | $11,025.21 | 11 |
| AbbVie, Inc. | $10,877.75 | 12 |
| Gilead Sciences, Inc. | $9,470.98 | 19 |
| Janssen Biotech, Inc. | $7,350.70 | 11 |
| Verastem, Inc. | $6,359.66 | 9 |
| Aurobindo Pharma USA, Inc. | $4,843.92 | 7 |
| Spectrum Pharmaceuticals Inc. | $3,687.11 | 10 |
| Pharmacyclics LLC, An AbbVie Company | $3,116.35 | 5 |
| EISAI INC. | $105.63 | 1 |
Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NILANJAN GHOSH
NPI 1205035466 · CMS profile ID 1223061
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
CHARLOTTE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NILANJAN GHOSH, NPI 1205035466, CMS profile ID 1223061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). NILANJAN GHOSH, NPI 1205035466, CMS profile ID 1223061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- NILANJAN GHOSH, NPI 1205035466, CMS profile ID 1223061, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1205035466?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
155 matching records · $131,531.04 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 155.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $23.16 | 08/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672935703 | CMS |
| Celgene Corporation | $113.69 | 08/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672936849 | CMS |
| Celgene Corporation | $25.00 | 08/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672962837 | CMS |
| Celgene Corporation | $1,099.10 | 08/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672963051 | CMS |
| Seattle Genetics, Inc. | $2,500.00 | 08/01/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678800117 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $600.00 | 07/30/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665709381 | CMS |
| Janssen Biotech, Inc. | $11.36 | 07/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658444161 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 07/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685881653 | CMS |
| AbbVie, Inc. | $60.58 | 07/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082933 | CMS |
| AbbVie, Inc. | $20.00 | 07/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082935 | CMS |
| AbbVie, Inc. | $3,150.00 | 06/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082917 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.46 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685361969 | CMS |
| AstraZeneca Pharmaceuticals LP | $723.14 | 06/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685878817 | CMS |
| Janssen Biotech, Inc. | $2,200.00 | 06/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658444157 | CMS |
| AbbVie, Inc. | $373.10 | 06/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082911 | CMS |
| AbbVie, Inc. | $116.38 | 06/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082931 | CMS |
| AbbVie, Inc. | $202.13 | 06/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082927 | CMS |
| AbbVie, Inc. | $116.38 | 06/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648082929 | CMS |
| Janssen Biotech, Inc. | $96.91 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658444152 | CMS |
| Celgene Corporation | $565.00 | 06/01/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672850701 | CMS |
| Gilead Sciences, Inc. | $23.00 | 05/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679342853 | CMS |
| Gilead Sciences, Inc. | $36.64 | 05/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679342855 | CMS |
| Gilead Sciences, Inc. | $13.88 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681517427 | CMS |
| Gilead Sciences, Inc. | $14.87 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681517429 | CMS |
| Gilead Sciences, Inc. | $49.30 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681517431 | CMS |
| Seattle Genetics, Inc. | $104.15 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678800077 | CMS |
| Kite Pharma, Inc. | $3,900.00 | 05/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662141707 | CMS |
| Kite Pharma, Inc. | $88.37 | 05/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662141683 | CMS |
| Kite Pharma, Inc. | $719.64 | 05/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662141711 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 05/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685285475 | CMS |
| Gilead Sciences, Inc. | $4,010.00 | 05/21/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679258597 | CMS |
| Janssen Biotech, Inc. | $2,200.00 | 05/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658444143 | CMS |
| Celgene Corporation | $265.07 | 05/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672840829 | CMS |
| Celgene Corporation | $550.10 | 05/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672869389 | CMS |
| Janssen Biotech, Inc. | $487.49 | 05/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658444136 | CMS |
| Janssen Biotech, Inc. | $85.00 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658444139 | CMS |
| Gilead Sciences, Inc. | $296.72 | 05/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679342845 | CMS |
| Gilead Sciences, Inc. | $747.73 | 05/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679342849 | CMS |
| Gilead Sciences, Inc. | $24.59 | 05/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681517421 | CMS |
| Gilead Sciences, Inc. | $44.59 | 05/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681517423 | CMS |
| Gilead Sciences, Inc. | $47.23 | 05/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681517425 | CMS |
| AstraZeneca Pharmaceuticals LP | $101.14 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685622123 | CMS |
| AstraZeneca Pharmaceuticals LP | $676.35 | 05/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685915317 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 05/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685085831 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 05/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685717977 | CMS |
| Celgene Corporation | $3,955.00 | 05/02/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672797415 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $600.00 | 04/30/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665705879 | CMS |
| Kite Pharma, Inc. | $6.03 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662142173 | CMS |
| Kite Pharma, Inc. | $4.61 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662142175 | CMS |
| Kite Pharma, Inc. | $4,050.00 | 04/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662142357 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,307.30 | 5 |
| PY2025 | Principal investigator | $578,284.72 | 16 |
| PY2024 | Principal investigator | $744,155.30 | 65 |
| PY2023 | Recipient | $350.00 | 2 |
| PY2023 | Principal investigator | $1,366,338.45 | 65 |
| PY2022 | Recipient | $4,450.00 | 6 |
| PY2022 | Principal investigator | $187,988.92 | 50 |
| PY2021 | Recipient | $4,262.33 | 3 |
| PY2021 | Principal investigator | $627,370.00 | 163 |
| PY2020 | Principal investigator | $1,261,300.44 | 134 |
| PY2019 | Recipient | $2,461.00 | 2 |
| PY2019 | Principal investigator | $1,073,264.50 | 134 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
21 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $65,062.50 | 12/18/2025 | Non-covered Recipient Entity SWOG CLINICAL TRIALS INITIATIVE LLC | Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma, S2308 | No dispute reported | 06/30/2026 | 1211660792 |
| Recipient | F. Hoffmann-La Roche AG | $616.07 | 12/12/2025 | Covered Recipient Physician | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211538056 |
| Recipient | F. Hoffmann-La Roche AG | $460.12 | 12/10/2025 | Covered Recipient Physician | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211538061 |
| Recipient | ABBVIE INC. | $725.00 | 12/05/2025 | Covered Recipient Physician | A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL | No dispute reported | 06/30/2026 | 1202398474 |
| Principal investigator 1 | ABBVIE INC. | $1,784.58 | 12/04/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202528648 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $625.35 | 11/14/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223263776 |
| Principal investigator 1 | ABBVIE INC. | $3,398.32 | 11/05/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202521693 |
| Principal investigator 1 | ABBVIE INC. | $256.16 | 09/04/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | No dispute reported | 06/30/2026 | 1202404384 |
| Principal investigator 1 | ABBVIE INC. | $65.63 | 09/04/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | No dispute reported | 06/30/2026 | 1202404387 |
| Principal investigator 1 | Incyte Corporation | $298.00 | 08/15/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) | No dispute reported | 06/30/2026 | 1240480181 |
| Principal investigator 1 | ABBVIE INC. | $256.16 | 07/03/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | No dispute reported | 06/30/2026 | 1202404380 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $105,369.32 | 06/25/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY HEALTH SCIENCES CLINICAL TRIALS OFFIC | A Modular Phase I and II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) | No dispute reported | 06/30/2026 | 1185543478 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $316,826.42 | 06/17/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) | No dispute reported | 06/30/2026 | 1236001789 |
| Recipient | F. Hoffmann-La Roche AG | $781.11 | 06/17/2025 | Covered Recipient Physician | To evaluate safety tolerability and efficacy of TCB | No dispute reported | 06/30/2026 | 1211538065 |
| Recipient | ABBVIE INC. | $725.00 | 06/12/2025 | Covered Recipient Physician | A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL | No dispute reported | 06/30/2026 | 1202398471 |
| Principal investigator 1 | ABBVIE INC. | $256.16 | 04/24/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | No dispute reported | 06/30/2026 | 1202404372 |
| Principal investigator 1 | ABBVIE INC. | $179.32 | 04/24/2025 | Covered Recipient Teaching Hospital ATRIUM HEALTH UNION | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | No dispute reported | 06/30/2026 | 1202404377 |
| Principal investigator 1 | Genentech, Inc. | $10,664.71 | 04/11/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211540145 |
| Principal investigator 1 | Genentech, Inc. | $4,246.82 | 02/13/2025 | Covered Recipient Teaching Hospital Atrium Health Cabarrus | To evaluate safety tolerability and efficacy of TCB | No dispute reported | 06/30/2026 | 1211540142 |
| Principal investigator 1 | ABBVIE INC. | $29,900.02 | 02/06/2025 | Non-covered Recipient Entity WAKE FOREST UNIVERSITY | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202448182 |
| Principal investigator 1 | ABBVIE INC. | $39,095.25 | 01/23/2025 | Covered Recipient Teaching Hospital CAROLINAS MEDICAL CENTER | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | No dispute reported | 06/30/2026 | 1202407265 |